Biomolecules & Therapeutics
Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis
Annamneedi Venkata Prakash, Jun Woo Park, Ju-Won Seong and Tae Jin Kang*
Convergence Research Center, Department of Pharmacy and Institute of Chronic Disease, Sahmyook University, Seoul 01795, Republic of Korea
Tel: +82-2-3399-1608, Fax: +82-2-3399-1617
Received: January 1, 2020; Revised: February 11, 2020; Accepted: February 17, 2020; Published online: March 5, 2020.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The process of drug discovery and drug development consumes billions of dollars to bring a new drug to the market. Drug development is time consuming and sometimes, the failure rates are high. Thus, the pharmaceutical industry is looking for a better option for new drug discovery. Drug repositioning is a good alternative technology that has demonstrated many advantages over de novo drug development, the most important one being shorter drug development timelines. In the last two decades, drug repositioning has made tremendous impact on drug development technologies. In this review, we focus on the recent advances in drug repositioning technologies and discuss the repositioned drugs used for inflammatory diseases such as sepsis, asthma, and atopic dermatitis.
Keywords: Drug repositioning, Inflammatory disease, Sepsis, Asthma, Atopic dermatitis

This Article

Cited By Articles
  • CrossRef (0)